Jagsonpal Pharmaceuticals Ltd reports Q2FY27 consolidated revenue of ₹96.4 crore, up 29% year on year
- Consolidated EBITDA was ₹18.6 crore at a 19.3% margin; PAT was ₹12.3 crore at a 12.8% margin.
- Standalone Q2 revenue rose 9.3% to ₹81.4 crore; EBITDA was ₹18.5 crore and PAT ₹12.6 crore.
- Standalone H1FY27 revenue increased 9.0% to ₹163.6 crore, with PAT up 10.3% to ₹25.8 crore.
- Q2 results included a ₹20 lakh exceptional expense related to the Aequitas acquisition.